Business
Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":" BEDFORD, Mass.--(BUSINESS WIRE)--\nOcular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company’s Board of Directors effective September 20, 2021.\n\n“We are excited to welcome Merilee to our Board of Directors,” said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. “Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from start-up to the multinational it is today. Her guidance and input will be invaluable as we seek to grow Ocular into a strategic leader in the ophthalmology space.”\n\nMs. Raines brings deep experience as a former public company financial executive having served 28 years with IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing. During her career at IDEXX, Ms. Raines held multiple positions of increasing responsibilities and served as the Company’s Executive Vice President and Chief Financial Officer at her retirement in May 2013. Ms. Raines is also an experienced independent board director and currently serves as a member of the Board of Directors of Transmedics Group, Inc. (NASDAQ:TMDX), Watts Water Technologies, Inc. (NYSE:WTS) and Excelitas Technologies Corporation, a private company. She holds a M.B.A. from University of Chicago, an A.B. from Bowdoin College and is a Certified Public Accountant (inactive status).\n\n“Ocular has successfully leveraged its hydrogel platform to bring an innovative product in DEXTENZA® to market and emerge as a highly-focused ophthalmology company with a pipeline of differentiated products designed to drive long-term growth,” said Ms. Raines. “I am pleased to be joining Ocular and the other members of its Board during this exciting period.”\n\nAbout Ocular Therapeutix, Inc.\n\nOcular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorba...